尽管同比收入平稳,Amphastar Pharma的收入超过了2025年第三季度的预期,收入为191.8万美元,每股收益为0.93美元,这得益于BAQSIMI的增长和新产品. Amphastar Pharma beat earnings estimates in Q3 2025 with $191.8M revenue and $0.93 EPS, driven by BAQSIMI growth and new products, despite flat year-over-year revenue.

Amphastar制药公司报告,2025年第三季度,其收入为1.918亿美元,调整后的收入为每股0.93美元,尽管年同比收入不变,但仍超过预期。 Amphastar Pharmaceuticals reported $191.8 million in third-quarter 2025 revenue and adjusted earnings of $0.93 per share, exceeding expectations despite flat year-over-year revenue. 增长的驱动因素是BAQSIMI销售量和新产品发行量增加了14%,包括林业发展局批准的铁苏格罗斯注射。 Growth was driven by a 14% increase in BAQSIMI® sales and new product launches, including FDA-approved iron sucrose injection. 该公司完成了向BAQSIMI全球分配的过渡,取消了先前的第三方收入。 The company completed its transition to global BAQSIMI® distribution, eliminating prior third-party revenue. 虽然一些产品由于竞争和定价压力而面临下降,但战略性管道投资和内部制造支持了业绩。 While some products faced declines due to competition and pricing pressures, strategic pipeline investments and in-house manufacturing supported performance. 业务利润率下降,预测的短期增长仍然不大。 Operating margins declined, and near-term growth forecasts remain modest.